Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELEVATE-45 study of ENTR-601-45 in Duchenne muscular dystrophy amenable to exon 45 skipping
NL-OMON59372Phase 2Recruiting
- Sponsor
- Entrada Therapeutics
- Start
- Nov 2025
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ENTR-601-45 in Duchenne muscular dystrophy (DMD) (3 arms), sponsored by Entrada Therapeutics. Primary endpoints: Incidence and severity of treatment emergent adverse events, Changes in vital sign measurements and 3 more. Started Nov 2025; status: recruiting.
02
Drugs
ENTR-601-45
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NL-OMON59372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59372.